source
- Viridian may have edge over Amgen in eye drug showdown, analysts argueThe FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.BioPharma Dive · 1mo ago↗ source
- These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.BioPharma Dive · 1mo ago↗ source
- Beeline ups its Series A round for immune drug workThe company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.BioPharma Dive